Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination

Han, Shengna; Yang, Wei; Yin, Jun; Tao, Hailong; Zhang, Lirong

doi:10.1007/s40256-018-00317-1

Cited by 10 publications

(5 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with a clear past history of hyperlipidaemia and/or a current serum lipid test that met criteria according to the 2016 Chinese Guidelines were diagnosed with dyslipidaemia. 17 …”

Section: Methodsmentioning

confidence: 99%

“…TC, TG, LDL-C, HDL-C, apolipoprotein A1 (Apo-A1) and apolipoprotein B (Apo-B) analyses were carried out using the cholesterol esterase/peroxidase enzymatic method,12 glycerophosphate oxidase/peroxidase enzymatic method,13 direct surfactant removal method,14 direct immunoinhibition method15 and immunoturbidimetry method,16 respectively, according to the manufacturers’ instructions. Patients with a clear past history of hyperlipidaemia and/or a current serum lipid test that met criteria according to the 2016 Chinese Guidelines were diagnosed with dyslipidaemia 17…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study

Huang

2022

BMJ Open

View full text Add to dashboard Cite

BackgroundDyslipidaemia is different among patients with hypertension in different populations. The serum lipid profiles among Hakka patients with hypertension in southern China are still unclear.Methods35 448 patients with hypertension were enrolled in this study from January 2016 to October 2020, and their serum lipids were analysed.ResultsLow high-density lipoprotein-cholesterol (HDL-C) (29.9%) accounted for the highest proportion in dyslipidaemia, followed by high triglyceride (TG) (20.7%), high total cholesterol (TC) (14.0%) and high low-density lipoprotein-cholesterol (LDL-C) (7.9%) in all subjects. The largest proportion of dyslipidaemia types was independent low HDL-C (12.7%). The proportion of low HDL-C was 15.5% in non-elderly men, 6.4% in non-elderly women, 16.7% in elderly men and 8.5% in elderly women, respectively. The largest proportion of dyslipidaemia types was independent high TG in non-elderly female patients (13.7%) and elderly patients (8.9%). The results showed that higher LDL-C, TC and TG levels in non-elderly patients than elderly patients. TG, TC and LDL-C levels decreasing with the increasing age, the differences were statistically significant. The levels of TG, TC, HDL-C and LDL-C in women were higher than in men among various age groups. Homocysteine level was increasing with increasing age.ConclusionsSerum lipid levels varied in different groups according to age and sex in patients with hypertension. Dyslipidaemia is more common in non-elderly patients than elderly. TG, TC and LDL-C levels were higher in female patients than male.

show abstract

“…Patients with a clear past history of hyperlipidaemia and/or a current serum lipid test that met criteria according to the 2016 Chinese Guidelines were diagnosed with dyslipidaemia. 17 …”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study

Huang

2022

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Ezetimibe and simvastatin combination therapy regularly decreases LDL-C more effectively than statin monotherapies, in accordance with a number of clinical research studies findings. Additionally, the combination therapy's safety and tolerability profiles appear to be comparable to those of lowdose statin monotherapies (18). Similarly, evidence from randomized controlled studies conducted on a number of individuals revealed that adding ezetimibe to statins, as opposed to increasing the statin dose, resulted in significantly more patients meeting their LDL-C goals and much fewer patients stopping their medication due to adverse effects (19).…”

Section: Evidence From Literaturementioning

confidence: 95%

Role of Ezetimibe and Statins in Dyslipidemia Patients

Alsubhi,

Alshalfan,

Alahmary

et al. 2023

JOHS

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of premature mortality globally. It is associated with significant morbidity and socioeconomic burden henceforth numerous initiatives have been taken to lower the risk in patients through preventive measures. The pathogenesis and progression of nearly all cardiovascular diseases are primarily caused by atherosclerosis and the association of cardiovascular disease risk to dyslipidemia is well-established since it increases the risk of cardiovascular events. Therefore, managing cholesterol, especially low-density lipoprotein, to reduce the burden of atherosclerotic plaque and, potentially, future cardiac complications, has been a key component of preventive measures. Due to its simplicity in dosage, lack of significant medication interactions, and favourable safety profile, statins have been the gold standard therapy for the treatment of dyslipidemia. However, the need for combined therapy arises when statin medication alone is insufficient to effectively reduce increased cholesterol levels. Ezetimibe is frequently added to regimens to support cholesterol reduction by preventing cholesterol absorption. Combinations of statin and ezetimibe may be a beneficial treatment choice for high-risk individuals who necessitate further lowering of cholesterol. Studies in the literature demonstrate that statin plus ezetimibe combined therapy is more beneficial and safer than high-intensity statin monotherapy, which implies that adding ezetimibe to statin should be favoured over increasing statin dose and that high-intensity statin is needed to be administered more carefully, especially in patients with related risks. The purpose of this research is to review the role of ezetimibe and statins in dyslipidemia patients.

show abstract

“…Twelve mice were fed a normal chow diet (NCD, #D12450B (# represents the Article Number); 10% kcal fat, 20% kcal protein, and 70% kcal carbohydrate) (NCD: corn, soybean meal, wheat bran, wheat flour, soybean oil, fish meal, calcium hydrogen phosphate, stone powder, salt, choline chloride, lysine, multiple vitamins, and mineral elements) (Xiao Shu You Tai Biotechnology Co., Ltd., Beijing, China), and twenty-four mice were fed a HFD (#D12492; 60% kcal fat, 20% kcal protein, and 20% kcal carbohydrate) (HFD: add lard, egg yolk powder, and cholesterol to NCD) to establish the diet-induced obesity (DIO) model for 18 weeks. Simvastatin (Sim) was selected as a positive drug to study the effect of ADe on blood lipids [ 31 ]. ADe fruiting body was dried and ground, and then mixed with normal saline to 80 or 160 mg/mL, and Sim mixed with normal saline to 0.6 mg/mL.…”

Section: Methodsmentioning

confidence: 99%

Anti-Obesity Effect of Auricularia delicate Involves Intestinal-Microbiota-Mediated Oxidative Stress Regulation in High-Fat-Diet-Fed Mice

Zhai

Wang

et al. 2023

Nutrients

View full text Add to dashboard Cite

Auricularia delicate (ADe), an edible fungus belonging to the family Auriculariaceae and order Auriculariales, possesses antimicrobial, hepatoprotective, and antioxidant effects. In this study, after systematic analysis of its composition, ADe was administered to high-fat-diet (HFD)-fed mice to investigate its anti-obesity effect. ADe significantly controlled body weight; alleviated hepatic steatosis and adipocyte hypertrophy; reduced aspartate aminotransferase, total cholesterol, insulin, and resistin; and increased adiponectin levels in HFD-fed mice serum. Based on intestinal microbiota and lipidomics analysis, ADe treatment regulated the composition and abundance of 49 intestinal microorganisms and influenced the abundance of 8 lipid species compared with HFD-fed mice. Based on a correlation analysis of the intestinal microbiota and lipids, Coprococcus showed significant negative associations with ceramide (d18:0 20:0+O), phosphatidylserine (39:4), sphingomyelin (d38:4), and zymosterol (20:2). Moreover, ADe treatment decreased the levels of ROS and MDA and increased the levels of Nrf2, HO-1, and three antioxidant enzymes in HFD-fed mice livers. Collectively, the anti-obesity effect of ADe involves the regulation of oxidative stress and is mediated by the intestinal microbiota. Hence, this study provides a reference for the application of ADe as a candidate food for obesity.

show abstract

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination

Cited by 10 publications

References 99 publications

Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study

Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study

Role of Ezetimibe and Statins in Dyslipidemia Patients

Anti-Obesity Effect of Auricularia delicate Involves Intestinal-Microbiota-Mediated Oxidative Stress Regulation in High-Fat-Diet-Fed Mice

Contact Info

Product

Resources

About